MedWorm: Oncology

Feed Category: 

Current Techniques of Prostate Biopsy Current Techniques of Prostate Biopsy

Find out how the techniques and technology of the prostate biopsy have evolved in recent years -- and learn how these changes could impact the field of prostate cancer diagnosis.Translational Andrology and Urology (Source: Medscape Today Headlines)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

Feed Item Url: 
https://medworm.com/822426372/current-techniques-of-prostate-biopsy-current-techniques-of-prostate-biopsy/

Diagnoses of several common health conditions HALVED during pandemic, study shows

The number of heart disease patients diagnosed also fell 44 per cent, as health services saw a 43 per cent plunge in patients with circulatory issues and 16 per cent drop in malignant cancers. (Source: the Mail online | Health)

Feed Item Url: 
https://medworm.com/822425256/diagnoses-of-several-common-health-conditions-halved-during-pandemic-study-shows/

Bowel cancer warning: A traditional dish may increase your risk of the deadly disease

BOWEL cancer can be a nasty condition that can shorten your life. If you'd like to lower your chances of developing the disease, you may fare better to stay away from one traditional dish. (Source: Daily Express - Health)

Feed Item Url: 
https://medworm.com/822427089/bowel-cancer-warning-a-traditional-dish-may-increase-your-risk-of-the-deadly-disease/

Lorlatinib: Another First-Line Option for ALK-Positive NSCLC? Lorlatinib: Another First-Line Option for ALK-Positive NSCLC?

First-line lorlatinib significantly prolonged progression-free survival compared with crizotinib in advanced ALK-positive nonsmall cell lung cancer, according to a phase 3 interim analysis.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)

Feed Item Url: 
https://medworm.com/822376464/lorlatinib-another-first-line-option-for-alk-positive-nsclc-lorlatinib-another-first-line-option-/

UK cancer research could see £ 167 million drop in funding as a result of charity income loss

(National Cancer Research Institute) Due to the impact of the Covid-19 pandemic, cancer research charities are predicting their spending on research could drop by 46%, equating to £ 167m. Charities play a vital role in UK cancer research. Data collected by the National Cancer Research Institute (NCRI) shows that in the year 2018/19, charities accounted for over 50% of publicly funded cancer research, a total of £ 362m. (Source: EurekAlert! - Cancer)

Feed Item Url: 
https://medworm.com/822376572/uk-cancer-research-could-see-167-million-drop-in-funding-as-a-result-of-charity-income-loss/

ADC Therapeutics Submits Biologics License Application to the U.S. Food and Drug Administration for Loncastuximab Tesirine for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

LAUSANNE, Switzerland--(BUSINESS WIRE)-- September 24, 2020 -- ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody... (Source: Drugs.com - New Drug Applications)MedWorm Message: If you are looking to buy something in the January Sales please visit TheJanuarySales.com for a directory of all the best sales in the UK. Any income gained via affiliate links keeps MedWorm running.

Feed Item Url: 
https://medworm.com/822394653/adc-therapeutics-submits-biologics-license-application-to-the-us-food-and-drug-administration-for-/

Zydus Cadila gets tentative USFDA nod to market anti-cancer drug

Drug firm Zydus Cadila on Thursday said it has received tentative approval from the US health regulator to market anti-cancer drug Palbociclib Capsules. (Source: The Economic Times Healthcare and Biotech News)

Feed Item Url: 
https://medworm.com/822442185/zydus-cadila-gets-tentative-usfda-nod-to-market-anti-cancer-drug/

Best of Cancer Research

This collection of articles from The Scientist explores some of the latest cancer research! (Source: The Scientist)

Feed Item Url: 
https://medworm.com/822321258/best-of-cancer-research/

Kubtec touts study on specimen biopsy system

Kubtec's 3D Mozart specimen biopsy system reduces the need for breast cancer...Read more on AuntMinnie.comRelated Reading:
Kubtec adds patents for breast cancer imaging
Kubtec will debut new specimen tomo system at RSNA 2018
Kubtec adds feature to specimen imaging systems
Kubtec x-ray devices help image ancient mummies
Kubtec to highlight tomo image analytics at RSNA 2017 (Source: AuntMinnie.com Headlines)

Feed Item Url: 
https://medworm.com/822282720/kubtec-touts-study-on-specimen-biopsy-system/

Pages